{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086344","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.231200+00:00","generated_at":"2026-05-31T12:08:01.099450+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cryoport Q2 net loss $78M including $63.8M goodwill impairment; FY24 guidance cut to $225-235M","bullets":["Revenue $57.6M (+1% YoY, +5.5% sequentially); Life Sciences Services up 8%, Products down 10%.","GAAP EPS loss $1.62 (diluted); Adjusted EBITDA negative $3.8M vs. negative $1.3M a year ago.","Recorded $63.8M impairment charge related to MVE Biological Solutions goodwill write-off.","FY 2024 revenue guidance revised to $225-235M from prior range; expects positive adjusted EBITDA in 2025.","Announced $200M stock/note repurchase program; repurchased $160M of 2026 convertible notes for $141.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086344","json":"https://secwatch.observer/filing/0001104659-24-086344.json","markdown":"https://secwatch.observer/filing/0001104659-24-086344.md","text":"https://secwatch.observer/filing/0001104659-24-086344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465924086344/0001104659-24-086344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465924086344/tm2421008d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:08:01.099450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}